| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 04/07/2005 | US20050075339 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 04/07/2005 | US20050075335 Pharmaceutical composition comprising n((1-n-butyl-4-piperidinyl)methyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indole-10-carboxamide or salt and process therefor comprising dry granulation |
| 04/07/2005 | US20050075334 Novel compounds |
| 04/07/2005 | US20050075330 Dipeptidyl peptidase inhibitors |
| 04/07/2005 | US20050075329 S-tofisopam, a prodrug or a salt thereof, free of its R enantiomer, and a carrier; may also contain one or more other anticonvulsants |
| 04/07/2005 | US20050075328 Such as (2'-methoxy-[1,1'-biphenyl]-4-yl)-(5H,11H-pyrrolo[2,1-c][1,4]benzodiazepin-10-yl)methanone; for treatment of diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, or hemophilia |
| 04/07/2005 | US20050074841 DNAs encoding mammalian histamine receptor of the H4 subtype |
| 04/07/2005 | US20050074797 FHIT proteins and nucleic acids and methods based thereon |
| 04/07/2005 | US20050074770 Cloned mammalian histamine H4 receptor that couples to G-protein; for use in diagnosis, prevention and treatment of asthma, allergy, inflammation, thrombotic, cardiovascular and autoimmune disorders |
| 04/07/2005 | US20050074751 Binding viral protein during latency life cycle; binding of antibodies to excellular segments of protein; immobilization; removal of infecting cells; autoimmune disease, lupus, antiarthritic agents |
| 04/07/2005 | US20050074470 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 04/07/2005 | US20050074436 Systems and methods for treating patients with processed lipoaspirate cells |
| 04/07/2005 | US20050074404 Methods for avoiding renal injury |
| 04/07/2005 | CA2540355A1 Phenylene derivative having tetrazole ring or thiazolidinedione ring |
| 04/07/2005 | CA2538215A1 Staple oligonucleotides and medicaments comprising the same |
| 04/06/2005 | EP1520855A1 Thieno(2,3-b)pyridine derivatives useful as antagonists of gonadotropin releasing hormone |
| 04/06/2005 | EP1519933A1 Quinuclidine amide derivatives |
| 04/06/2005 | EP1519920A1 Novel tetrahydropyridine derivatives as renin inhibitors |
| 04/06/2005 | EP1519915A2 Tricyclic steroid hormone nuclear receptor modulators |
| 04/06/2005 | EP1519754A1 Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents |
| 04/06/2005 | EP1519747A2 Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| 04/06/2005 | EP1519746A1 Use of digoxin immune fab for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients |
| 04/06/2005 | EP1519733A1 Compositions for cancer therapy comprising saponins or sapogenins |
| 04/06/2005 | EP1519732A1 Use of vasopeptidase inhibitors in the treatment of nephropathy |
| 04/06/2005 | EP1519730A1 Novel use of imidazotriazinones |
| 04/06/2005 | EP1519720A2 Novel formate salt of o-desmethyl-venlafaxine |
| 04/06/2005 | EP1353909B1 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioidreceptor binding agents |
| 04/06/2005 | EP1090012A4 Inhibitors of prenyl-protein transferase |
| 04/06/2005 | EP1090011A4 Inhibitors of prenyl-protein transferase |
| 04/06/2005 | EP0984930B1 2-indolinone derivatives as modulators of protein kinase activity |
| 04/06/2005 | EP0912521B1 Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) |
| 04/06/2005 | EP0748219B1 Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
| 04/06/2005 | CN1604965A 生长激素融合蛋白 Growth hormone fusion protein |
| 04/06/2005 | CN1604904A Phosphonic acid compounds as inhibitors of serine proteases |
| 04/06/2005 | CN1604901A Bicyclic oxopyridine and oxopyrimidine derivatives |
| 04/06/2005 | CN1604900A 6-aminomorphinane derivatives, method for production and use thereof |
| 04/06/2005 | CN1604898A 3-heteroaryl-3, 5-dihydro-4-oxo-4h-pyridazino[4, 5-b]indole-1-carboxamide derivatives, their preparation, their intermediates and pharmaceutical compositions containing the compounds |
| 04/06/2005 | CN1604793A Methods of treatment and formulations of cephalosporin |
| 04/06/2005 | CN1604791A 访问控制系统 Access Control System |
| 04/06/2005 | CN1604783A Drug for treating a fibrotic disease through rna interfence |
| 04/06/2005 | CN1604777A Method of treatment |
| 04/06/2005 | CN1603314A Pyrazolobenzodiazepines as CDK2 inhibitors |
| 04/06/2005 | CN1602929A Traditional Chinese medicine composition for treating nephritis and uraemia |
| 04/06/2005 | CN1602923A Chinese traditional medicine for treating kidney disease and nephrotic syndrome and its preparation method |
| 04/06/2005 | CN1602920A Gingko leaf extracts with superior quality and its manufacturing technique |
| 04/06/2005 | CN1602918A Astragalus root and Breviscapine containing Chinese medicinal formulation and its preparation and application |
| 04/06/2005 | CN1602898A Prostate hyperplasia treating medicine by fatsoluble active constituent of winged euony twigs and its preparation process |
| 04/06/2005 | CN1602897A Prostatitis treating plaster |
| 04/06/2005 | CN1602880A Method for inhibitting bone resorption |
| 04/06/2005 | CN1602879A Method for inhibitting bone resorption |
| 04/06/2005 | CN1195773C Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 04/06/2005 | CN1195743C Dihydro-1, 3, 5-triazine amine derivatives and their therapeutic uses |
| 04/06/2005 | CN1195545C Vaginal suppository vaccine for urogenital infections |
| 04/06/2005 | CN1195540C Medicine for treating chronic prostatitis and preparation thereof |
| 04/06/2005 | CN1195522C Benzodiazepine derivatives |
| 04/06/2005 | CN1195521C Use of quinazoline compounds for the treatment of polycystic kidney disease |
| 04/05/2005 | US6875886 Modified PSMA ligands and uses related thereto |
| 04/05/2005 | US6875779 Cyclooxygenase inhibitor |
| 04/05/2005 | US6875777 Compounds |
| 04/05/2005 | US6875775 Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 04/05/2005 | US6875570 Proteins and nucleic acids encoding same |
| 04/05/2005 | US6875450 Comestible for preventing calcium oxalate urolithiasis in canine animals |
| 03/31/2005 | WO2005028463A1 Cinnamoyl compound and use of the same |
| 03/31/2005 | WO2005028455A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient |
| 03/31/2005 | WO2005028441A1 Cinnamoyl derivatives and use thereof |
| 03/31/2005 | WO2005028439A1 Cinnamoyl compound and use of the same |
| 03/31/2005 | WO2005028438A1 Novel piperidine derivative |
| 03/31/2005 | WO2005028426A1 Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor |
| 03/31/2005 | WO2005028032A1 Injectable therapeutic formulations |
| 03/31/2005 | WO2005027923A1 Use of vitamin d3 analogue for the treatment of benign prostatic hyperplasia |
| 03/31/2005 | WO2005027899A1 Use of fumaric acid derivatives for the prophylaxis and treatment of genome damage |
| 03/31/2005 | WO2004108133A3 Modulators of vr1 receptor |
| 03/31/2005 | WO2003099215A3 Antisense modulation of glucocorticoid receptor expression |
| 03/31/2005 | WO2003073987A3 Compounds that modulate the activity of ptp-1b and tc-ptp |
| 03/31/2005 | WO2003040329A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 03/31/2005 | WO2003018756A3 Methods for preparing purified prostaglandin e synthase |
| 03/31/2005 | US20050070720 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| 03/31/2005 | US20050070713 Neurokinin antagonist; therapy for central nervous system disorders; psychological disorders; Parkinson's and Huntington's disease |
| 03/31/2005 | US20050070706 Antidiabetic agents; obesity; controlling appetite |
| 03/31/2005 | US20050070689 Nucleotide sequences coding transmembrane activator and CAML interactor (TACI) protein for use in treatment and prevention of autoimmune disorders |
| 03/31/2005 | US20050070590 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity |
| 03/31/2005 | US20050070574 Novel compounds |
| 03/31/2005 | US20050070569 Alkyne-aryl phosphodiesterase-4 inhibitors |
| 03/31/2005 | US20050070566 Imidazoquinoline derivatives |
| 03/31/2005 | US20050070558 For example, [4-(2,4-Dioxo-1,3-dipropyl-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetic acid; useful in preventing mast cell degranulation and therefore useful in treatment of diseases induced by activation of A2b receptor and mast cell activation such as asthma, allergic reactions |
| 03/31/2005 | US20050070555 Aroyl pyridinones |
| 03/31/2005 | US20050070541 Enzyme inhibitors of cGMP-metabolizing phosphodiesterases, for TREATMENT OF CARDIOVASCULAR DIORDERS, CEREBROVASCULAR DISORDERS, UROGENITAL DISORDERS AND ERECTILE DYSFUNCTION; chemical synthesis |
| 03/31/2005 | US20050070535 Antidiabetic agents; obesity; controlling appetite |
| 03/31/2005 | US20050070531 Using such as 2-[2-(3-Amino-piperidin-1-yl)4-oxo-4H-quinazolin-3-ylmethyl]-benzonitrile to treat cancer and/or autoimmune disorder |
| 03/31/2005 | US20050070530 Dipeptidyl peptidase inhibitors |
| 03/31/2005 | US20050070480 Peptide arginals and methods for treating disseminated intravascular coagulation |
| 03/31/2005 | US20050070470 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| 03/31/2005 | US20050070459 treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor |
| 03/31/2005 | US20050070014 Method of expressing foreign gene in kidney |
| 03/31/2005 | US20050069946 Expression analysis of FKBP54 in the diagnosis and treatment of prostate cancer |
| 03/31/2005 | US20050069876 Polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune, inflammatory, cardiovascular, neurological and developmental disorders. |
| 03/31/2005 | US20050069598 Antidiabetic agents; moderate glucagon-like peptide; phosphoenolpyruvate carboxykinase inhbitors; weight control |
| 03/31/2005 | US20050069547 Binding protein; therapy for bone tumors |
| 03/31/2005 | US20050069537 Stimulants of survival of cells; binding of cellular adhesion molecular; prevent apoptosis |
| 03/31/2005 | US20050069533 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof |